Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from AstraZeneca ( (GB:AZN) ).
AstraZeneca has secured European Union approval for its immunotherapy Imfinzi, in combination with standard FLOT chemotherapy, as the first perioperative immunotherapy regimen for adults with resectable early-stage and locally advanced gastric and gastroesophageal junction cancers. The decision, based on the Phase III MATTERHORN trial, further consolidates the company’s position in early-stage oncology and broadens Imfinzi’s role as a backbone therapy across solid tumours.
The MATTERHORN data showed that adding Imfinzi to chemotherapy reduced the risk of disease progression, recurrence or death by 29% and cut the risk of death by 22% versus chemotherapy alone, with survival benefits increasing over time and observed regardless of PD-L1 status. With a safety profile consistent with existing uses and similar surgery completion rates, the regimen is expected to become a new standard of care in Europe, strengthening AstraZeneca’s competitive footing in gastrointestinal cancer and complementing approvals already granted in the U.S. and other markets, while additional regulatory reviews continue globally.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £16496.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
Spark’s Take on AZN Stock
According to Spark, TipRanks’ AI Analyst, AZN is a Outperform.
The score is driven primarily by strong underlying financial performance and a constructive earnings outlook (growth guidance and pipeline progress). This is tempered by valuation (P/E ~30), recent free-cash-flow variability, and technical signals that appear overextended despite the broader uptrend.
To see Spark’s full report on AZN stock, click here.
More about AstraZeneca
AstraZeneca is a global biopharmaceutical company focused on the discovery, development and commercialization of prescription medicines, with a strong presence in oncology. Its portfolio includes targeted therapies, immunotherapies and chemotherapy combinations for cancers such as lung, gastrointestinal, liver, bladder and gynecologic malignancies across early and advanced disease settings.
Average Trading Volume: 2,753,780
Technical Sentiment Signal: Buy
Current Market Cap: £223B
For an in-depth examination of AZN stock, go to TipRanks’ Overview page.